Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-09-30
2008-09-09
Kemmerer, Elizabeth C. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S094100, C424S094640
Reexamination Certificate
active
07423009
ABSTRACT:
The present invention relates to a composition for prevention and treatment of kidney diseases comprising one or more effective component(s) of a PAR-2 activating agent which is able to activate PAR-2 and a pharmaceutically acceptable carrier. The present invention further relates to a method for prevention and treatment of kidney diseases comprising administration of a composition for prevention and treatment of kidney diseases containing a PAR-2 activating agent which is able to activate PAR-2 to patients suffering from kidney diseases, and also relates to the use of a PAR-2 activating agent which is able to activate PAR-2 for the manufacture of a composition for prevention and treatment of kidney diseases. The present invention furthermore relates to a method for screening an effective ingredient for prevention and treatment of kidney diseases comprising screening of the activating action of the test substance to PAR-2.
REFERENCES:
patent: WO 01/74390 (2001-10-01), None
Rondeau, et al, 2001, Nephrol. Dial. Transplant., 16: 1529-1531.
Gee, et al, 1985, Biochem., 228: 119-126.
Bertog, Marko, et al. “Basolateral proteinase-activated receptor (PAR-2) induces chloride secretion in M-1 mouse renal cortical collecting duct cells”.Journal of Physiology(1999), 521-1, pp. 3-17.
Gui, Yu, et al. “Bidirectional regulation of renal hemodynamics by activation of PAR1and PAR2in isolated perfused rat kidney.”Am J Physical Renal Physiol285: F95-104, 2003.
Trottier, Greg, et al. “PAR-2 elicits afferent arteriolar vasodilation by NO-dependent and NO-independent actions.”Am J Physical Renal Physiol282: F891-897, 2002.
Grandaliano, Giuseppe, et al. “Protease-Activated Receptor 2 Expression in IgA Nephropathy: A Potential Role in the Pathogenesis of Interstitial Fibrosis.”J Am Soc Nephrol14: 2072-2083, 2003.
LeHir, Michel, et al. “IL-12-Dependent, IFN-γ-Independent Experimental Glomerulonephritis.”Kidney Blood Press Res2001; 24-27-32.
Ito, Mikio, et al. “Crescentic Type Nephritis Induced By Anti-Glomerular Basement Membrane (GBM) Serum in Rats.”Japan J. Pharmacol. 33, 1145-1154 (1983).
Kawabata, Atsufumi, et al. “Activation of Protease-Activated Receptor-22 (PAR-2) Triggers Mucin Secretion in the Rat Sublingual Gland.”Biochemical and Biophysical Research Communications270, 298-302 (2000).
Bahjat, Al-Ani, et al. “Detection of functional receptors for the proteinase-activated-receptor-2-activating polypeptide, SLIGRL-NH2, in rat vascular and gastric smooth muscle.”Can. J. Physiol. Pharmacol. vol. 73, 1203-1207 (1995).
Kong, Wuyi, et al. “Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2.”Proc. Natl. Acad. Sci.,USA vol. 94 pp. 8884-8889 (Aug. 1997).
Molino, Maria, et al. “Endothelial Cell Thrombin Receptors and PAR-2.”The Journal of Biological Chemistryvol. 272, No. 17 pp. 11133-11141 (Apr. 25, 1997).
Ferrell, William R., et al. “Essential role for proteinase-activated receptor 2 in arthritis.”The Journal of Clinical Investigationvol. 111, No. 1 (Jan. 2003).
Kawagoe, Junichi, et al. “Effect of Protease-Activated Receptor-2 Deficiency on Allergic Dermatitis in the Mouse Ear.”Japan J. Pharmacol. 88, 77-84 (2002).
Lindner, Jonathan, et al. “Delayed Onset of Inflammation in Protease-Activated-Receptor-2-Deficient Mice.”The Journal of Immunologypp. 6504-6510, Copyright 2000 by the American Association of Immunologists.
Kanke, Toru, et al. “Proteinase-activated Receptor-2 mediated Activation of Stress-activated Protein Kinases and Inhibitory κB Kinases in NCTC 2544 Keratinocytes.”The Journal of Biological Chemistry, vol. 276, No. 34, pp. 31657-31666 (Aug. 24, 2001).
Hou, L., et al. “Immunolocalization of protease-activated receptor-2 in skin: receptor activation stimulates interleukin-8 secretion by keratinocytes in vitro.”Immunology94, 356-362, Copyright 1998 Blackwell Science Ltd.
Compton, Steven J. et al. “The Role ofMast Cell Tryptase in Regulating Endothelial Cell Proliferation, Cytokine Release, and Adhesion Molecule Expression: Tryptase Induces Expression of mRNA for IL-1β and IL-8 and Stimulates the Selective Release of IL-8 from Human Umbilical Vein Endothelial Cells.”The Journal of Immunology, pp. 1939-1946, Copyright 1998 by the American Association of Immunologists.
He, Shaoheng, et al. “Potent Induction of a Neutrophil and Eosinophil-Rich Infiltrate In Vivo by Human Mast Cell Tryptase: Selective Enhancement of Eosinophil Recruitment by Histamine.”The Journal of Immunology, pp. 6216-6225, Copyright 1997 by the American Association of Immunologists.
Vergnolle, Nathalie “Proteinase-Activated Receptor-2-Activating Peptides Induce Leukocyte Rolling, Adhesion, and Extravasation in Vivo.”The Journal of Immunology, pp. 5064-5069, Copyright 1999 by the American Association of Immunologists.
Steinhoff, M., et al. “Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanis,.”Nature Medicinevol. 6, No. 2 (Feb. 2000).
He, Shaoheng and Walls, A. “Human mast cell tryptase: a stimulus of microvascular leakage and mast cell activation.”European Journal of Pharmacology, 328 (1997) 89-97.
Vergnolle, Nathalie, et al. “Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw.”British Journal of Pharmacology(1999) 127, 1083-1090.
Kawabata, Atsufumi, et al. “Increased vascular permeability by a specific agonist of protease-activated receptor-2 in rat hindpaw.”British Journal of Pharmacology(1998) 125, 419-422.
Smith-Swintosky, et al. “Protease-Activated Receptor-2 (PAR-2) Is Present in the Rat Hippocampus and Is Associated with Neurodegeneration.”Journal of Neurochemistrypp. 1890-1896 Copyright 1997 International Society for Neurochemistry.
Damiano, Bruce P., et al. “Increased Expression of Protease Activated Receptor-2 (PAR-2) in Balloon-Injured Rat Cartotid Artery.”Thromb Haemost1999; 81:808-14.
Cicala, Carla, et al. “Protease-Activated Receptor-2 Involvement in Hypotension in Normal and Endotoxemic Rats in Vivo.” www.circulationaha.org. Circulation May 1999, vol. 99: 2590-2597.
MacFarlane, Scott R., et al. “Proteinase-Activated Receptors.”Pharmacol Rev53:245-282, 2001.
Roy, Samir. S., et al. “Dual endothelium-dependent vascular activities of proteinase-activated receptor-2-activating peptides: evidence for receptor heterogeneity.”British Journal of Pharmacology(1998) 123, 1434-1440.
Matsui-Nakanishi, Mayumi, et al. “PAR3 is a cofactor for PAR4 activation by thrombin.”Naturevol. 404, pp. 609-613 Apr. 6, 2000.
Nystedt, Sverker, et al. “Molecular cloning of a potential proteinase activated receptor.”Proc. Natl. Acad. Sci. USAvol. 91, pp. 9208-9212, Sep. 1994.
Koichi Hayashi et al.,Antihypertensive Drugs(Kouatsuyaku)—Treatement of Hypertension Involving Renal Damage, Igaku No Ayumi, kidney diseases (Jinshikkan)—state of arts (Ver. 2), Ishiyaku Publishers, Inc., 1997, pp. 158-161.
European Search Report dated Jul. 7, 2007 in PCT/JP0312472.
Sebekova et al.: “Systemic treatment with proteolytic enzymes in rat models of nonimmune mediated :renal diseases” International Journal of Immunotherapy, Bioscience Ediprint Inc., vol. 13, No. ¾, 1997, pp. 79-83.
Emancipator et al.: “Oral enzymes in different animal models of glomerulonephritis”, International Journal of Immunotherapy, Bioscience Ediprint Inc., vol. 13, No. ¾, 1997, pp. 97-103.
Damioan Bruce P et al.: “Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1”, Journal of Pharmacology and Experimental Therapeutics, vol. 288, No. 2, Feb. 1999, pp. 671-678, Dam
Ishiwata Hiroyuki
Kanke Toru
Kawagoe Junichi
Nakagawa Takashi
Takizawa Toshiaki
Kemmerer Elizabeth C.
Kowa Company Ltd.
Wegert Sandra
Westerman, Hattori, Daniels & Adrian , LLP.
LandOfFree
Method for treatment of kidney diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment of kidney diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment of kidney diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3984441